With Cellartis reprogramming services, we will deliver high-quality human iPS cell lines from your PBMC or fibroblast samples. The cells will be reprogrammed using footprint-free Sendai virus technology to ensure no viral integration.

The reprogramming service can start with sending us your cell samples, or alternatively, you may elect to use Cellartis sourcing services to help you find exactly the right PBMCs to create a custom iPS cell line. Once the reprogramming service begins, the starting material will be prepared for reprogramming; one iPS cell clone will be established in the Cellartis DEF-CS 500 Culture System, then expanded into a stable iPS cell line, banked, and characterized.

Thawing of your (or sourced) cells, propagation as applicable

Reprogramming using Sendai virus

Picking of colonies

Selection of clones and generation of seed banks

Expansion of high-quality clone to Master Cell Bank (viral clearance confirmed)

QC and characterization of Master Cell Bank (see QC testing section, below)

Delivery of hiPS cell line to customer

PBMC reprogramming

Fibroblast reprogramming

Included with the reprogramming service:

• Visual inspection and confirmation of the morphologies of the cells in the starting material and in the Master Cell Bank
• Immunocytochemistry of the cells in the Master Cell Bank to verify the presence of the pluripotency markers Oct-4, SSEA-4, TRA-1-60, and TRA-1-81, and the absence of SSEA-1
• Sterility testing of the Master Cell Bank (bacteria, including Mycoplasma)
• Confirmation that no Sendai virus vector remains in the cells

Additional testing and characterization services for reprogrammed cells:

• Cellartis Descriptive Karyotyping Service (Cat. #Y60304)
  • Karyotype analysis of 20 G-banded metaphase spreads from reprogrammed cells will be performed.
• Cellartis Spontaneous In Vitro Differentiation Service (Cat. #Y60305)
  • A 3-week spontaneous in vitro differentiation protocol will be used on a subset of reprogrammed cells. Cells will be fixed and immunolabelled for ASMA (mesoderm), FoxA2 (endoderm), and βIII-tubulin (ectoderm) to confirm trilineage potential.
• Cellartis STR Analysis Service (Cat. #Y60306)
  • Genomic DNA will be isolated from reprogrammed iPS cells and the corresponding starting material. Short tandem repeat (STR) analysis will be performed on 16 loci to verify there are no differences between the samples.

You may wish to submit your own fibroblast or PBMC samples for Cellartis reprogramming services or use Cellartis sourcing services to find custom starting materials. If you would like us to start with your cells, we will need:

• Fibroblasts: 5 vials (1 million cells per vial) of customer-provided fibroblasts, with relevant information regarding culturing and freezing protocols
• PBMCs: 5 vials (10 million cells per vial) of customer-provided PBMCs, with relevant information regarding culturing and freezing protocols

For safety and QC purposes, we can only work with human samples that are free of human pathogens and that have passed a sterility test. We require documentation proving that all samples shipped to us are sterile and pathogen-free. In the absence of documentation, testing for pathogens (Cat. #Y60301) and sterility (Cat. #Y60302) will be performed via a third-party service prior to the initiation of Cellartis services. Please note that safety and sterility testing will incur additional lead time and costs.

1. Submit the service inquiry form below.
2. We contact you to go over your project requirements and provide a quote.
3. Place your order and ship us the necessary cells and documentation to initiate the service. (Does not apply if using our sourcing service.)
4. We perform the agreed-upon service according to the designated lead times.
5. We provide you with the agreed-upon deliverables.
   
   

   Note: Takara Bio Europe, AB (TBEAB) will perform the reprogramming service only one time per purchase. Each purchase of the reprogramming service includes one transduction attempt with Sendai virus per donor sample. If a successful reprogramming cannot be achieved after the transduction of the donor sample with Sendai virus, the reprogramming service will be terminated and neither TBUSA nor TBEAB will have any further obligation, including additional attempts of the reprogramming service. If additional work is required, TBUSA will discuss such work, pricing, and lead time with the customer.